Skip to main content
2024 ISPE Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Amir Sarayani, PhamrD, MPH, PhD (he/him/his)

Associate Director
Janssen Research & Development, Johnson & Johnson, United States

Amir Sarayani started his professional career as a pharmacist, clinical researcher, and hospital pharmacy executive in academia. He then earned his Ph.D. specializing in pharmacoepidemiology, where he advanced novel approaches to assess risk minimization programs and studied drug interactions using a multidisciplinary framework. As a pharmacoepidemiologist in the Department of Global Epidemiology at Johnson & Johnson (J&J), Amir is the J&J lead for joint PASS studies in a cross-pharma consortium to evaluate risk minimization, leads epidemiology strategy for a novel Alzheimer’s drug candidate, and contributes to cross-therapeutic area initiatives including Active Safety Surveillance Using Real-World Evidence (ASSURE), and J&J Pregnancy and Lactation (JJ-PAL) Advisory Group. Amir's scholarship includes over seventy scientific publications, leading articles in Annals of Internal Medicine, BMJ Quality & Safety, and Epidemiology. He serves as a courtesy Assistant Professor, College of Pharmacy University of Florida, and co-chairs ISPE’s BRACE Special Interest Group leading risk communication & minimization workstream. Amir’s scientific mission is to advance innovation, equity, and evidence-based decision-making in the healthcare industry.

Disclosure information not submitted.

Presentation(s):

Email Amir